These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34697172)

  • 1. COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection.
    Guler-Margaritis S; Mercan-Stanciu A; Toma L; Rusie D; Isac T; Dodot M; Zgura A; Bacalbasa N; Haineala B; Badiu DC; Serban D; Iliescu EL
    In Vivo; 2021; 35(6):3377-3383. PubMed ID: 34697172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
    Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
    J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    Tabu K; Mawatari S; Oda K; Kumagai K; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Fujisaki K; Imanaka D; Kure T; Taniyama O; Toyodome A; Ijuin S; Sakae H; Sakurai K; Moriuchi A; Kanmura S; Ido A
    PLoS One; 2020; 15(8):e0237475. PubMed ID: 32790728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?
    Isfordink CJ; Maan R; de Man RA; van Erpecum KJ; van der Meer AJ
    Eur J Intern Med; 2021 Dec; 94():6-14. PubMed ID: 34563447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
    Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
    J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
    J Viral Hepat; 2021 May; 28(5):710-718. PubMed ID: 33481322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
    Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
    Yeh ML; Hung CH; Tseng KC; Lai HC; Chen CY; Kuo HT; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang CF; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Liu CJ; Yu ML
    Hepatol Int; 2021 Oct; 15(5):1109-1121. PubMed ID: 34365587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.